Chemotherapy treatments induce a number of side effects, such as
leukopenia neutropenia, peripheral erythropenia, and
thrombocytopenia, affecting the quality of life for
cancer patients.
5-Fluorouracil (5-FU) is wieldy used as myeloablative model in mice. The bovine
dialyzable leukocyte extract (bDLE) or IMMUNEPOTENT CRP® (ICRP) is an immunomodulatory compound that has
antioxidants and anti-inflammatory effects. In order to investigate the chemoprotection effect of ICRP on bone marrow cells in
5-FU treated mice, total bone marrow (BM) cell count, bone marrow colony forming units-granulocyte/macrophage (CFU-GM), cell cycle, immunophenotypification, ROS/
superoxide and Nrf2 by flow cytometry, and histological and hematological analyses were performed. Our results demonstrated that ICRP increased BM cell count and CFU-GM number, arrested BM cells in G0/G1 phase, increased the percentage of leukocyte, granulocytic, and erythroid populations, reduced ROS/
superoxide formation and Nrf2 activation, and also improved hematological levels and
weight gain in
5-FU treated mice. These results suggest that ICRP has a chemoprotective effect against
5-FU in BM cells that can be used in
cancer patients.